Zakeri, Nekisa http://orcid.org/0000-0003-1167-1160
Hall, Andrew
Swadling, Leo http://orcid.org/0000-0002-0537-6715
Pallett, Laura J. http://orcid.org/0000-0002-4161-9462
Schmidt, Nathalie M. http://orcid.org/0000-0002-9841-8418
Diniz, Mariana O.
Kucykowicz, Stephanie
Amin, Oliver E. http://orcid.org/0000-0003-3663-1253
Gander, Amir
Pinzani, Massimo
Davidson, Brian R.
Quaglia, Alberto
Maini, Mala K. http://orcid.org/0000-0001-6384-1462
Funding for this research was provided by:
Wellcome Trust (175479, 214191)
Cancer Research UK (26603)
Article History
Received: 29 May 2021
Accepted: 17 February 2022
First Online: 16 March 2022
Competing interests
: Unrelated to the content of this manuscript, authors M.K.M. and N.M.S. have an international patent application No.1917498.6 entitled Treatment of Hepatitis B Virus (HBV) Infection filed by applicant UCL Business Ltd. MP is co-founder and director of Engitix Therapeutics Ltd, UK. The Maini lab has received unrestricted funding from Gilead, Roche and Immunocore. The remaining authors declare no competing interests.